These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1066 related items for PubMed ID: 12975010

  • 21. Immunogenicity, safety, and cross-reactivity of an inactivated, adjuvanted, prototype pandemic influenza (H5N1) vaccine: a phase II, double-blind, randomized trial.
    Wu J, Fang HH, Chen JT, Zhou JC, Feng ZJ, Li CG, Qiu YZ, Liu Y, Lu M, Liu LY, Dong SS, Gao Q, Zhang XM, Wang N, Yin WD, Dong XP.
    Clin Infect Dis; 2009 Apr 15; 48(8):1087-95. PubMed ID: 19281330
    [Abstract] [Full Text] [Related]

  • 22. Safety and immunogenicity profile of the concomitant administration of ZOSTAVAX and inactivated influenza vaccine in adults aged 50 and older.
    Kerzner B, Murray AV, Cheng E, Ifle R, Harvey PR, Tomlinson M, Barben JL, Rarrick K, Stek JE, Chung MO, Schödel FP, Wang WW, Xu J, Chan IS, Silber JL, Schlienger K.
    J Am Geriatr Soc; 2007 Oct 15; 55(10):1499-507. PubMed ID: 17908055
    [Abstract] [Full Text] [Related]

  • 23. Immunogenicity and safety of low dose virosomal adjuvanted influenza vaccine administered intradermally compared to intramuscular full dose administration.
    Künzi V, Klap JM, Seiberling MK, Herzog C, Hartmann K, Kürsteiner O, Kompier R, Grimaldi R, Goudsmit J.
    Vaccine; 2009 Jun 02; 27(27):3561-7. PubMed ID: 19464535
    [Abstract] [Full Text] [Related]

  • 24. Open, randomized study to compare the immunogenicity and reactogenicity of an influenza split vaccine with an MF59-adjuvanted subunit vaccine and a virosome-based subunit vaccine in elderly.
    Ruf BR, Colberg K, Frick M, Preusche A.
    Infection; 2004 Aug 02; 32(4):191-8. PubMed ID: 15293073
    [Abstract] [Full Text] [Related]

  • 25. Safety and immunogenicity of trivalent inactivated influenza vaccine in infants: a randomized double-blind placebo-controlled study.
    Englund JA, Walter E, Black S, Blatter M, Nyberg J, Ruben FL, Decker MD, GRC28 Study Team.
    Pediatr Infect Dis J; 2010 Feb 02; 29(2):105-10. PubMed ID: 19934787
    [Abstract] [Full Text] [Related]

  • 26. [Safety and immunogenicity on three lots of influenza split vaccines among adults].
    Zhang ZL, Wang X, Zhu XJ, Zhang Y, Liu Y, Gao ZG, Liang M, Li L, Li JM, Liu RK, Dong XJ, Song GX, Zhang DC, Wang WQ, Han YG, Chen JT.
    Zhonghua Liu Xing Bing Xue Za Zhi; 2009 Jun 02; 30(6):583-7. PubMed ID: 19957624
    [Abstract] [Full Text] [Related]

  • 27. Safety and immunogenicity of live attenuated and inactivated influenza vaccines in children with cancer.
    Carr S, Allison KJ, Van De Velde LA, Zhang K, English EY, Iverson A, Daw NC, Howard SC, Navid F, Rodriguez-Galindo C, Yang J, Adderson EE, McCullers JA, Flynn PM.
    J Infect Dis; 2011 Nov 15; 204(10):1475-82. PubMed ID: 21949042
    [Abstract] [Full Text] [Related]

  • 28. Immunogenicity and safety of a novel liposomal influenza subunit vaccine (INFLUSOME-VAC) in young adults.
    Ben-Yehuda A, Joseph A, Zeira E, Even-Chen S, Louria-Hayon I, Babai I, Zakay-Rones Z, Greenbaum E, Barenholz Y, Kedar E.
    J Med Virol; 2003 Apr 15; 69(4):560-7. PubMed ID: 12601765
    [Abstract] [Full Text] [Related]

  • 29. Vaccination against influenza in patients with rheumatoid arthritis: the effect of rituximab on the humoral response.
    Oren S, Mandelboim M, Braun-Moscovici Y, Paran D, Ablin J, Litinsky I, Comaneshter D, Levartovsky D, Mendelson E, Azar R, Wigler I, Balbir-Gurman A, Caspi D, Elkayam O.
    Ann Rheum Dis; 2008 Jul 15; 67(7):937-41. PubMed ID: 17981914
    [Abstract] [Full Text] [Related]

  • 30. Safety and immunogenicity of a novel influenza subunit vaccine produced in mammalian cell culture.
    Szymczakiewicz-Multanowska A, Groth N, Bugarini R, Lattanzi M, Casula D, Hilbert A, Tsai T, Podda A.
    J Infect Dis; 2009 Sep 15; 200(6):841-8. PubMed ID: 19673651
    [Abstract] [Full Text] [Related]

  • 31. Dose sparing with intradermal injection of influenza vaccine.
    Kenney RT, Frech SA, Muenz LR, Villar CP, Glenn GM.
    N Engl J Med; 2004 Nov 25; 351(22):2295-301. PubMed ID: 15525714
    [Abstract] [Full Text] [Related]

  • 32. Immunogenicity and safety of influenza A (H1N1) 2009 monovalent inactivated split vaccine in Korea.
    Cheong HJ, Song JY, Heo JY, Noh JY, Choi WS, Park DW, Wie SH, Kim WJ.
    Vaccine; 2011 Jan 10; 29(3):523-7. PubMed ID: 21055502
    [Abstract] [Full Text] [Related]

  • 33. Immunogenicity and safety of a China-made monovalent pandemic (H1N1) 2009 influenza A vaccine in healthcare workers in Guangzhou, China.
    Zhan Y, Yang Z, Li L, Ye D, Wu H, Fu R, Zhao S, Wang Y, Zhou R, Chen R.
    Jpn J Infect Dis; 2011 Jan 10; 64(3):190-4. PubMed ID: 21617301
    [Abstract] [Full Text] [Related]

  • 34. Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children.
    Nolan T, Richmond PC, Formica NT, Höschler K, Skeljo MV, Stoney T, McVernon J, Hartel G, Sawlwin DC, Bennet J, Ryan D, Basser RL, Zambon MC.
    Vaccine; 2008 Nov 25; 26(50):6383-91. PubMed ID: 18801398
    [Abstract] [Full Text] [Related]

  • 35. [Safety and immunological effect of domestic split influenza virus vaccine].
    Zhang PR, Zhu XP, Zhou LJ, Liu YQ, Fan Y, Chen G, Chen Z, Liu Y, Sun HY, Wu JL.
    Zhonghua Yu Fang Yi Xue Za Zhi; 2009 Jul 25; 43(7):615-8. PubMed ID: 19954075
    [Abstract] [Full Text] [Related]

  • 36. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy children aged 6-59 months.
    King JC, Cox MM, Reisinger K, Hedrick J, Graham I, Patriarca P.
    Vaccine; 2009 Nov 05; 27(47):6589-94. PubMed ID: 19716456
    [Abstract] [Full Text] [Related]

  • 37. A TritonX-100-split virion influenza vaccine is safe and fulfills the committee for proprietary medicinal products (CPMP) recommendations for the European Community for Immunogenicity, in Children, Adults and the Elderly.
    Lina B, Fletcher MA, Valette M, Saliou P, Aymard M.
    Biologicals; 2000 Jun 05; 28(2):95-103. PubMed ID: 10885616
    [Abstract] [Full Text] [Related]

  • 38. A Phase III randomised trial of the immunogenicity and safety of quadrivalent versus trivalent inactivated subunit influenza vaccine in adult and elderly subjects, assessing both anti-haemagglutinin and virus neutralisation antibody responses.
    van de Witte S, Nauta J, Montomoli E, Weckx J.
    Vaccine; 2018 Sep 25; 36(40):6030-6038. PubMed ID: 29709447
    [Abstract] [Full Text] [Related]

  • 39. Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial.
    Roman F, Vaman T, Gerlach B, Markendorf A, Gillard P, Devaster JM.
    Vaccine; 2010 Feb 17; 28(7):1740-5. PubMed ID: 20034605
    [Abstract] [Full Text] [Related]

  • 40. Immunogenicity of inactivated 2009 H1N1 influenza vaccine in pediatric liver transplant recipients.
    Torii Y, Kimura H, Ochi N, Kaneko K, Ando H, Kiuchi T, Ito Y.
    Vaccine; 2011 Jun 06; 29(25):4187-9. PubMed ID: 21513762
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 54.